Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
FEATURED AUTHORITIES ON RHEUMATOID ARTHRITIS MANAGAMENT
iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.
Course Videos
Video
Can you provide an overview of the mechanism of action of IL-6 inhibitors in RA, rationale for their use, and what we have learned from landmark trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?
Video
How do you differentiate among the available biologics with respect to their propensity to produce side effects or other treatment complications?
Video
Are there any specific patient profiles in RA or biomarker signatures that would suggest that an individual patient might respond better to one biologic DMARD and MOA — including IL-6 inhibition — versus another?
Video
Can you discuss the critical recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the recently reported EULAR guidelines for RA? How are they similar? How are they different? Where do IL-6 inhibitors ...
Video
The new EULAR guidelines—as well as ACR recommendations for RA management—are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors ...
Video
Considering the positive results from the SARIL-RA-TARGET, SARIL-RA-MOBILITY and EXTEND studies, as well as the recently reported MONARCH study, how do you differentiate among the agents and RA patients to identify ideal candidates for ...
Video
What are the major unmet needs in patients with RA?
What are the major unmet needs in patients with RA?
Video
Can the Simplified Disease Activity Index (SDAI) provide predictive information that guides aggressiveness of therapy for RA?
Video
What are predictors of risk progression and/or poor therapeutic response in RA that would make a patient appropriate for early, aggressive therapy with biologic therapy?
Video
How, why, and where should IL-6 cytokine inhibitors fit into evidence- and/or expert-based roadmaps for sequential approaches to RA management?
Video
Can you discuss the design and results of the TARGET trial?
Can you discuss the design and results of the TARGET trial?
Video
Should biologically-naïve patients be approached differently from patients who have been on a previous B-DMARD therapy, but have suboptimal clinical results? What is the role of IL-6 inhibitors in this population?
